Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real‐World Data from the Spanish Tumor Registry (R‐GETNE)

• Published in: The oncologist (Dayton, Ohio) Vol. 23; no. 4; pp. 422 - 432
• Main Authors: Nuñez‐Valdovinos, Barbara, Carmona‐Bayonas, Alberto, Jimenez‐Fonseca, Paula, Capdevila, Jaume, Castaño‐Pascual, Ángel, Benavent, Marta, Pi Barrio, Jose Javier, Teule, Alex, Alonso, Vicente, Custodio, Ana, Marazuela, Monica, Segura, Ángel, Beguiristain, Adolfo, Llanos, Marta, Martinez del Prado, Maria Purificacion, Diaz‐Perez, Jose Angel, Castellano, Daniel, Sevilla, Isabel, Lopez, Carlos, Alonso, Teresa, Garcia‐Carbonero, Rocio
• Format: Journal Article
• Language: English
• Published: United States AlphaMed Press 01-04-2018
• Subjects: Gastroenteropancreatic; Gastrointestinal Cancer; Heterogeneity; Ki‐67; Neuroendocrine neoplasms; Prognosis; Registry; Tumor differentiation; World Health Organization 2010; Neuroendocrine neoplasms; Heterogeneity; Prognosis; World Health Organization 2010; Ki‐67; Registry; Gastroenteropancreatic; Tumor differentiation
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.2017-0364

Background
Gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are a complex family of tumors of widely variable clinical behavior. The World Health Organization (WHO) 2010 classification provided a valuable tool to stratify neuroendocrine neoplasms (NENs) in three prognostic subgroups based on the proliferation index. However, substantial heterogeneity remains within these subgroups, and simplicity sometimes entails an ambiguous and imprecise prognostic stratification. The purpose of our study was to evaluate the prognostic impact of histological differentiation within the WHO 2010 grade (G) 1/G2/G3 categories, and explore additional Ki‐67 cutoff values in GEP‐NENs.
Subjects, Materials, and Methods
A total of 2,813 patients from the Spanish National Tumor Registry (RGETNE) were analyzed. Cases were classified by histological differentiation as NETs (neuroendocrine tumors [well differentiated]) or NECs (neuroendocrine carcinomas [poorly differentiated]), and by Ki‐67 index as G1 (Ki‐67 <2%), G2 (Ki‐67 3%–20%), or G3 (Ki‐67 >20%). Patients were stratified into five cohorts: NET‐G1, NET‐G2, NET‐G3, NEC‐G2, and NEC‐G3.
Results
Five‐year survival was 72%. Age, gender, tumor site, grade, differentiation, and stage were all independent prognostic factors for survival. Further subdivision of the WHO 2010 grading improved prognostic stratification, both within G2 (5‐year survival: 81% [Ki‐67 3%–5%], 72% [Ki‐67 6%–10%], 52% [Ki‐67 11%–20%]) and G3 NENs (5‐year survival: 35% [Ki‐67 21%–50%], 22% [Ki‐67 51%–100%]). Five‐year survival was significantly greater for NET‐G2 versus NEC‐G2 (75.5% vs. 58.2%) and NET‐G3 versus NEC‐G3 (43.7% vs. 25.4%).
Conclusion
Substantial clinical heterogeneity is observed within G2 and G3 GEP‐NENs. The WHO 2010 classification can be improved by including the additive effect of histological differentiation and the proliferation index.
Implications for Practice
Gastroenteropancreatic neuroendocrine neoplasms are tumors of widely variable clinical behavior, roughly stratified by the World Health Organization (WHO) 2010 classification into three subgroups based on proliferation index. Real‐world data from 2,813 patients of the Spanish Registry RGETNE demonstrated substantial clinical heterogeneity within grade (G) 2 and G3 neuroendocrine neoplasms. Tumor morphology and further subdivision of grading substantially improves prognostic stratification of these patients and may help individualize therapy. This combined, additive effect shall be considered in future classifications of neuroendocrine tumors and incorporated for stratification purposes in clinical trials.
This article evaluates the prognostic impact of histological differentiation within the WHO 2010 grading classifications and explores additional Ki‐67 cut‐off values for gastroenteropancreatic neuroendocrine neoplasms.